UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 32,270 Shares of Illumina, Inc. (NASDAQ:ILMN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,292,407 shares of the life sciences company's stock after acquiring an additional 32,270 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.81% of Illumina worth $172,704,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Vident Advisory LLC grew its holdings in Illumina by 1,269.2% in the fourth quarter. Vident Advisory LLC now owns 99,348 shares of the life sciences company's stock valued at $13,276,000 after purchasing an additional 92,092 shares during the last quarter. Spyglass Capital Management LLC acquired a new stake in shares of Illumina during the fourth quarter valued at $71,855,000. Triglav Skladi D.O.O. acquired a new stake in shares of Illumina during the fourth quarter valued at $1,403,000. Taconic Capital Advisors LP acquired a new stake in shares of Illumina during the fourth quarter valued at $668,000. Finally, Tidal Investments LLC boosted its stake in shares of Illumina by 740.3% during the fourth quarter. Tidal Investments LLC now owns 37,385 shares of the life sciences company's stock valued at $4,996,000 after acquiring an additional 32,936 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Up 0.4%

Shares of ILMN traded up $0.36 during midday trading on Wednesday, reaching $82.85. 616,148 shares of the stock were exchanged, compared to its average volume of 2,319,299. The firm has a 50 day simple moving average of $78.00 and a 200-day simple moving average of $107.72. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $156.66. The company has a market cap of $13.11 billion, a price-to-earnings ratio of -10.78, a P/E/G ratio of 1.60 and a beta of 1.35.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period last year, the business earned $0.98 EPS. The firm's revenue was down 1.4% compared to the same quarter last year. Research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on ILMN shares. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Morgan Stanley reduced their target price on Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research report on Monday, May 12th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and reduced their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Royal Bank of Canada reduced their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 8th. Finally, Barclays reduced their target price on Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and an average price target of $128.15.

Insider Buying and Selling at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the stock in a transaction on Monday, May 12th. The shares were purchased at an average price of $81.21 per share, with a total value of $495,381.00. Following the acquisition, the chief financial officer now directly owns 24,906 shares of the company's stock, valued at $2,022,616.26. This represents a 32.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 2.60% of the company's stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.